Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with mantle cell lymphoma (MCL) and in patients with Waldenstrom's macroglobulinemia (WM). The Company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

ASH 2012

Pharmacyclics had 9 oral and 9 poster presentations at this year's American Society of Hematology (ASH) Annual Meeting providing an update on the broad development program of ibrutinib.  Among the data presented at ASH were updates on the safety and efficacy of ibrutinib in the most mature clinical programs of chronic lymphocytic leukemia (CLL) and MCL. Two of the CLL oral presentations were acknowledged as 'Best of ASH' during the event. Additionally, investigators presented data in diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM).  Most of the oral presentations can be found on the Company's website. 

Phase II/III clinical trials initiated with ibrutinib in the collaboration:

  • Phase III study of ibrutinib versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), RESONATE™. This trial is a randomized, multi-center, open-label Phase III trial of ibrutinib as a monotherapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to ofatumumab. This global study is open and Pharmacyclics plans to enroll 350 patients worldwide. The Company anticipates having this st
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/22/2014)... The DNA Spectrum Ancestry ... representation of history, migration, and culture. , Throughout ... family history stories stemming from Europe. His father passionately ... Pictures and 8mm home movies painted an elaborate picture ... and Steve ordered a test from DNA Spectrum to ...
    (Date:7/22/2014)... SHENZHEN , Kina, 22. juli 2014 /PRNewswire/ ... et datterselskab af BGI, verdens største genomics-organisation, annoncerede ... exome-sekvenseringstjeneste baseret på Complete Genomics brancheførende platform. ... for at levere patenterede sekvenseringsteknologier med 99,999 % ... blev købt af BGI i 2013. Mere end ...
    (Date:7/22/2014)... Hussey Copper , a leader in copper manufacturing ... Pullman Regional Hospital,s conversion of more than 1,100 touch ... at a nominal cost.  This reasonably priced surface kills ... within 2 hours of exposure 1 and will aid ... in its facilities. Pullman Regional Hospital, in ...
    (Date:7/22/2014)... Quorum Review IRB, the industry leader in ... trials called Quick Step™ . The offering went live ... research industry’s need for seamless study start-up with a large ... studies planning 50 or more North American investigator sites, as ... site count of 80 or more. Qualifying studies may also ...
    Breaking Biology Technology:DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3
    ... FMC Corporation (NYSE: FMC ) announced ... exclusive agreements covering global development and supply of Chr. ... will begin commercialization this year of Chr. Hansen,s Nemix ... biological standalone and combination products in the Americas and ...
    ... NEW YORK, Aug. 23, 2011 ... research report is available in its ... (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue ... Forecast (2010-2015) ...
    ... Blocking a transport pathway through the brain cells offers new ... colleagues of VIB and K.U. Leuven discovered that two main ... beta precursor protein (APP) and the beta secretase enzyme (BACE1), ... up. It is during the eventual meeting between protein and ...
    Cached Biology Technology:FMC Corporation Announces Exclusive Global Development and Supply Agreements for Chr. Hansen Biological Products 2Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 2Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 3Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 4Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 5Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 6Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 7Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 8Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 9Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 10Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 11Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 12Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) 13
    (Date:7/22/2014)... squirrels have adapted to New York City,s human behaviour, ... better, than their fellow squirrels in the woods. , ... Environment & Agriculture, led the study that proved eastern ... urban environments and prevent unnecessary responses when humans acted ... footpath. , "As we rapidly increase the spread ...
    (Date:7/22/2014)... spot with natural tourism resources, a recent study revealed a ... Geoscience and Mineral Resources (KIGAM) indicated that there are the ... 5,000 years ago. That is the first time to actually ... volcano 5,000 years ago in the inland part of the ... The research team led by Dr. Jin-Young Lee confirmed in ...
    (Date:7/22/2014)... 2014 NXT-ID, Inc., (NXTD: OTCQB) a biometric authentication ... its next generation smart wallet, Wocket™, will be featured on ... that airs on the History Channel, FYI Network, ... features top technology products and services. The segment ... Channel (6:00-6:30am ET/PT) and the FYI Network (7:00-7:30am ...
    Breaking Biology News(10 mins):New York squirrels are nuts about city life 2Jeju Island is a live volcano 2NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 2NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 3
    ... and zanamivir, are highly effective when given as ... the influenza virus, according to an analysis of ... Research Center, University of Michigan and University of ... the American Journal of Epidemiology. The analysis also ...
    ... for granted when it is carried out by the ... when scientists devise new ways for molecules to self ... , Researchers with the Macromolecules and Interfaces Institute (MII ... development in the online issue for the Journal of ...
    ... Center have identified a subgroup of hard-to-treat breast cancers ... used in the treatment of breast tumors. They ... which may help identify patients most likely to benefit ... in a clinical trial anticipated to begin at the ...
    Cached Biology News:Antivirals effectively curb influenza virus 2Antivirals effectively curb influenza virus 3Molecular signature may identify cisplatin-sensitive breast tumors 2Molecular signature may identify cisplatin-sensitive breast tumors 3
    ... peptide transporter 2 (APT2) ... transporter PSF2) (Peptide supply ... transporter involved in antigen ... Antigen: ...
    Raised to arginine vasopressin coupled to bovine thyroglobulin with carbodiimide ....
    Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
    Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Biology Products: